Dtsch Med Wochenschr 2014; 139(21): 1127-1130
DOI: 10.1055/s-0034-1370044
Übersicht | Review article
Diabetologie
© Georg Thieme Verlag KG Stuttgart · New York

Prädisposition und Phänotypen des MODY – Implikationen für Diagnostik und Therapie

Predisposition and phenotype of MODY – implications for diagnosis and treatment
M. Hummel
1   Forschergruppe Diabetes der TU München
2   Diabetologische Schwerpunktpraxis Rosenheim
› Author Affiliations
Further Information

Publication History

09 February 2014

02 April 2014

Publication Date:
13 May 2014 (online)

 
  • Literatur

  • 1 Ellard S, Beards F, Allen LI et al. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia 2000; 43: 250-253
  • 2 Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345: 971-980
  • 3 Fendler W, Borowiec M, Baranowska-Jazwiecka A et al. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. Diabetologia 2012; 55: 2631-2635
  • 4 Hummel M, Vasseur F, Mathieu C et al. Two caucasian families with the hepatocyte nuclear factor-1alpha mutation Y218C. Exp Clin Endocrinol Diabetes 2007; 115: 62-64
  • 5 Knebel B, Müller-Wieland D, Kotzka J. MODY: Eine monogene Form der pankreatischen β-Zell-Dysfunktion. Diabetologie 2010; 5: 176-183
  • 6 Lango Allen H, Johansson S, Ellard S et al. Polygenic risk variants for type 2 diabetes susceptibility modify age at diagnosis in monogenic HNF1A diabetes. Diabetes 2010; 59, 11: 266-271
  • 7 McCarthy MI, Hattersley AT. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes 2008; 57: 2889-2898
  • 8 Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenetic β-cell diabetes. Nature Clinical Practice 2008; 4: 200-213
  • 9 Neu A, Feldhahn L, Ehehalt S et al. Type 2 diabetes mellitus in children and adolescents is still a rare disease in Germany: a population-based assessment of the prevalence of type 2 diabetes and MODY in patients aged 0-20 years. Pediatr Diabetes 2009; 10: 468-473
  • 10 Pearson ER, Velho G, Clark P et al. Beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations. Diabetes 2001; 50 (Suppl. 01) 101-107
  • 11 Shields BM, Hicks S, Shepherd MH et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing?. Diabetologia 2010; 53: 2504-2508
  • 12 Stride A, Shields B, Gill-Carey O et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 2014; 57: 54-56
  • 13 Stride A, Vaxillaire M, Tuomi T et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002; 45: 427-435
  • 14 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197